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Background: Polycystic ovary syndrome (PCOS) is the most frequent cause of anovulatory 93 
infertility. In women with PCOS, effective ovulation induction serves as an important first-line 94 
treatment for anovulatory infertility. Individual participant data (IPD) meta-analysis is 95 
considered as the gold standard for evidence synthesis which provides accurate assessments of 96 
outcomes from primary randomised controlled trials (RCTs) and allows additional analyses for 97 
time-to-event outcomes. It also facilitates treatment-covariate interaction analyses and 98 
therefore offers an opportunity for personalised medicine. 99 
Objective and rationale: We aimed to evaluate the effectiveness of different ovulation 100 
induction agents, in particular letrozole alone and clomiphene citrate (CC) plus metformin, as 101 
compared to CC alone, as the first-line choice for ovulation induction in women with PCOS 102 
and infertility, and to explore interactions between treatment- and participant-level baseline 103 
characteristics. 104 
Search methods: We searched electronic databases including MEDLINE, EMBASE and 105 
Cochrane Central Register of Controlled Trials up to 20th December 2018. We included RCTs 106 
comparing the following interventions with each other or placebo/ no treatment in women with 107 
PCOS and infertility: CC, metformin, CC plus metformin, letrozole, gonadotrophin and 108 
tamoxifen. We excluded studies on treatment-resistant women. The primary outcome was live 109 
birth. We contacted the investigators of eligible RCTs to share the IPD and performed IPD 110 
meta-analyses. We assessed the risk of bias by using the Cochrane risk of bias tool for RCTs. 111 
Outcomes: IPD of 20 RCTs including 3962 women with PCOS were obtained. Six RCTs 112 
compared letrozole and CC in 1284 women. Compared with CC, letrozole improved live birth 113 
rates (3 RCTs, 1043 women, risk ratio [RR] 1.43, 95% confidence interval [CI] 1.17-1.75, 114 
moderate-certainty evidence) and clinical pregnancy rates (6 RCTs, 1284 women, RR 1.45, 115 
95% CI 1.23-1.70, moderate-certainty evidence), and reduced time-to-pregnancy (6 RCTs, 116 
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1235 women, hazard ratio [HR] 1.72, 95%CI 1.38-2.15, moderate-certainty evidence). Meta-117 
analyses of effect modifications showed a positive interaction between baseline serum total 118 
testosterone levels and treatment effects on live birth (interaction RR 1.29, 95%CI 1.01-1.65). 119 
Eight RCTs compared CC plus metformin to CC alone in 1039 women. Compared with CC 120 
alone, CC plus metformin might improve clinical pregnancy rates (8 RCTs, 1039 women, RR 121 
1.18, 95% CI 1.00-1.39, low-certainty evidence) and might reduce time-to-pregnancy (7 RCTs, 122 
898 women, HR 1.25, 95%CI 1.00-1.57, low-certainty evidence), but there was insufficient 123 
evidence of a difference on live birth rates (5 RCTs, 907 women, RR 1.08, 95% CI 0.87-1.35, 124 
low-certainty evidence). Meta-analyses of effect modifications showed a positive interaction 125 
between baseline insulin levels and treatment effects on live birth in the comparison between 126 
CC plus metformin and CC (interaction RR 1.03, 95% CI 1.01-1.06). 127 
Wider implications: In women with PCOS, letrozole improves live birth and clinical 128 
pregnancy rates and reduces time-to-pregnancy compared to CC and therefore can be 129 
recommended as the preferred first-line treatment for women with PCOS and infertility. CC 130 
plus metformin may increase clinical pregnancy and may reduce time-to-pregnancy compared 131 
to CC alone, while there is insufficient evidence of a difference on live birth. Treatments effects 132 
of letrozole are influenced by baseline serum levels of total testosterone, while those of CC 133 
plus metformin are affected by baseline serum levels of insulin. These interactions between 134 
treatments and biomarkers on hyperandrogenaemia and insulin resistance provide further 135 
insights into a personalised approach for the management of anovulatory infertility related to 136 
PCOS. 137 
Key words: 138 
polycystic ovary syndrome, infertility, anovulation, ovulation induction, letrozole, clomiphene, 139 





Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of reproductive 143 
age women, and the prevalence among different geographic regions ranges from 5% to 21%, 144 
depending on the criteria used (Lizneva, et al., 2016). PCOS is a heterogeneous syndrome 145 
comprising of at least two of the following clinical characteristics according to the Rotterdam 146 
diagnostic criteria: oligo-/ anovulation, clinical and/or biochemical hyperandrogenism, or 147 
polycystic ovaries morphology based on ultrasound assessment (Rotterdam ESHRE/ASRM-148 
Sponsored PCOS Consensus Workshop Group, 2004). 149 
Anovulatory infertility is usually one of the key features that women with PCOS are confronted 150 
with. Simple and effective infertility treatments as the first-line choice are therefore important. 151 
Our previous network meta-analysis compared available first-line treatment options for women 152 
with PCOS with infertility and found that letrozole and combined clomiphene citrate (CC)-153 
metformin were superior to other ovulation induction medications in terms of clinical 154 
pregnancy and that letrozole resulted in more live births than other interventions, including CC 155 
(Wang, et al., 2017). These findings are in agreement with the evidence summarised in the 156 
International evidence based guideline for the assessment and management of PCOS (Teede, 157 
et al., 2018). 158 
As women with PCOS represent a heterogeneous population according to the diagnostic 159 
criteria, it is important to identify which individuals benefit most from a particular treatment 160 
so that clinicians can provide personalised care (Wang and Mol, 2017). However, primary 161 
RCTs are usually underpowered to detect subgroup effects (Riley, et al., 2010). Subgroup 162 
analyses in meta-analyses of aggregate data are at risk of ecological bias due to the ignorance 163 
of within-study interactions, or are even impossible to perform due to heterogeneous reporting 164 
of subgroup data in the primary trials (Riley, et al., 2010).  165 
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Moreover, time-to-pregnancy is also an important patient-centred outcome, but it has never 166 
been reported in previous meta-analyses on PCOS. This is likely due to the unavailability of 167 
the data in the publication as well as the methodological challenges on data extraction and 168 
synthesis. In addition, the primary trials are not always of high quality in terms of analyses and 169 
reports (Eshre Capri Workshop Group, 2018), which can directly affect the data extraction, 170 
analysis and risk of bias assessment process in subsequent meta-analyses. 171 
These deficiencies in aggregate data meta-analyses can potentially be overcome by using 172 
individual participant data (IPD). IPD meta-analysis has been described as the gold standard in 173 
evidence synthesis, by engaging investigators of the primary trials to provide the raw data of 174 
the primary trials (Broeze, et al., 2010). Such strategy facilitates derivation of the information 175 
beyond the primary publication, standardisation of inclusion criteria, outcomes and analyses 176 
across trials, and investigations of subgroup effects and time-to-event outcomes. (Broeze, et 177 
al., 2010, Riley, et al., 2010).  178 
We therefore performed an IPD meta-analysis to evaluate the effectiveness of different 179 
ovulation induction agents, in particular letrozole alone and CC plus metformin, as compared 180 
to CC alone, as the first-line choice for ovulation induction in women with PCOS and 181 
infertility, and to explore interactions between treatment- and participant-level baseline 182 




Registration and literature search 187 
This IPD meta-analysis was conducted based on a registered protocol (PROSPERO 188 
CRD42017059251) and reported according to the Preferred Reporting Items for Systematic 189 
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Review and Meta-Analyses of individual participant data (PRISMA-IPD) statement (Stewart, 190 
et al., 2015). 191 
We updated the searches in MEDLINE, EMBASE and Cochrane Central Register of 192 
Controlled Trials in September 2017, based on our previous search strategies for a network 193 
meta-analysis on treatment strategies for World Health Organization (WHO) II anovulation 194 
(Wang, et al., 2017). In brief, the search terms included both index terms as well as free words 195 
on PCOS, anovulation and ovulation induction. After completing data requesting process, we 196 
further updated the search on 20th December 2018 to identify the latest studies. We also 197 
searched the WHO International Clinical Trials Registry Platform (WHO ICTRP) and U.S. 198 
National Institutes of Health (clinicaltrials.gov) and ISRCTN registry to identify ongoing trials. 199 
In addition, we reviewed the references lists of relevant papers and corresponded with trialists 200 
in PCOS to identify potential eligible trials that we might have missed. 201 
 202 
Eligibility criteria 203 
We included RCTs comparing the following interventions with each other or placebo/no 204 
treatment: clomiphene citrate (CC), metformin, CC and metformin combined, letrozole, 205 
gonadotrophins and tamoxifen in women with WHO II anovulation, including PCOS. We 206 
excluded trials reporting on treatment-resistant women, trials comparing different doses of the 207 
same intervention and quasi-RCTs. We did not apply language restrictions. For crossover trials, 208 
we only included the data in the first phase. 209 
The primary outcome was live birth. The secondary outcomes were clinical pregnancy, 210 
ovulation, miscarriage, multiple pregnancy and time to pregnancy. 211 
 212 
Study selection and data collection 213 
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Two members of the review team (from RW, WL and EMB) independently assessed the titles 214 
and abstracts to exclude irrelevant studies and subsequently reviewed the full-text articles to 215 
evaluate their eligibility. Disagreements were resolved by discussion with a third author 216 
(BWM, MvW or RJN).  217 
We contacted investigators of eligible RCTs to share the de-identified IPD and established the 218 
International Ovulation Induction IPDMA Collaboration. We sent at least two more reminders 219 
when we did not receive responses. 220 
We obtained de-identified IPD including baseline characteristics including age, body mass 221 
index (BMI), ethnicity, type of infertility (primary/secondary), treatment history (treatment-222 
naïve or not), fasting glucose, fasting insulin, total testosterone, sex hormone binding globulin 223 
(SHBG), ovarian volume and the Ferriman-Gallwey score for hirsutism. We also obtained data 224 
on allocated treatments, number of ovulation induction cycles, ovulation and fertility outcomes 225 
including live birth, clinical pregnancy, miscarriage and multiple pregnancy.  226 
We checked data for consistency by comparing the analyses from obtained IPD with the 227 
original publications. We discussed any inconsistencies or obvious errors with investigators of 228 
primary RCTs and solved discrepancies by consensus.  229 
 230 
Risk of bias assessment 231 
Two members of the review team independently evaluated the risk of bias in each included 232 
RCT, using the domain-based evaluation tool described in the Cochrane Handbook for 233 
Systematic Reviews of Interventions (Higgins and Green, 2011). We assessed the following 234 
domains as low risk of bias, unclear or high risk of bias: random sequence generation, 235 
allocation concealment, blinding of participants and personnel, blinding of outcome assessors, 236 
incomplete outcome data, selective reporting (reporting bias) and other sources of bias. When 237 
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the risk of bias for a domain was unclear, investigators of these RCTs were asked to provide 238 
additional information to resolve the uncertainty.  239 
We assessed the overall certainty of the evidence across RCTs by using the Grading of 240 
Recommendations Assessment, Development and Evaluation (GRADE) approach, including 241 
the risk of bias, consistency of effect, imprecision, indirectness and publication bias. 242 
 243 
Data synthesis 244 
We conducted all analyses based on an intention-to-treat principle using woman randomised 245 
per allocated group as the unit of all analyses. We performed two-stage random-effects IPD 246 
meta-analyses for letrozole versus CC alone and CC with metformin versus CC alone. For 247 
dichotomous outcomes, we calculated risk ratios (RRs) and 95% confidence intervals (CIs) and 248 
presented statistical heterogeneity by using I2 statistic (Higgins and Green, 2011). For time-to-249 
event outcomes, we used the number of treatment cycles as an approximate estimate for time 250 
and visualised the summary time-to-event in simple non-stratified Kaplan-Meier curves. We 251 
also estimated hazard ratios (HR) in Cox proportional hazards regression models for discrete 252 
time and pooled HRs and 95% CI, by using the generic inverse variance method (Fisher, 2015).  253 
Subgroup effects were estimated for the primary outcome by treatment-covariate interaction 254 
terms within trials and subsequent meta-analyses of interactions, as interactions using within-255 
trials information alone without considering between-trials interactions are recommended as 256 
the standard practice to avoid ecological bias (Fisher, et al., 2017). We explored the treatment-257 
covariate interactions of the following pre-specified baseline covariates: age, BMI, ethnicity, 258 
primary/secondary infertility, treatment history, hirsutism score, insulin resistance (serum 259 
glucose and insulin level), hyperandrogenaemia status (testosterone, SHBG, free androgen 260 
index) and ovarian volume. We also added the analysis of homeostatic model assessment for 261 
insulin resistance (HOMA-IR) as requested during the peer review process.  For dichotomous 262 
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covariates with statistically significant interaction, we further performed stratified analyses to 263 
illustrate the treatment effects in different strata of the subgroups. Continuous variables were 264 
analysed as such without categorisation. For continuous covariates with statistically significant 265 
interaction, we further presented a weighted mean curve and pointwise confidence interval 266 
based on treatment-covariate interactions estimated in relevant studies. Due to the potential 267 
type I error, the results of subgroup analyses were all considered exploratory. 268 
To evaluate the IPD availability bias, we performed a network meta-analysis of RCTs with IPD 269 
in a random-effects multivariate meta-analysis model (Riley, et al., 2017, White, 2015) on live 270 
birth and clinical pregnancy, and then compared the results with a network meta-analysis of all 271 
eligible RCTs. If these results were consistent, we considered the included RCTs with IPD 272 
representative of all the eligible RCTs. 273 
We performed a sensitivity analysis on studies with low risk of bias in allocation concealment 274 
as planned. As the majority of eligible studies focused only on treatment-naïve women with 275 
PCOS, these studies did not contribute to within-study interaction for treatment history and 276 
were not included in the treatment-covariate analysis. We performed a post-hoc sensitivity 277 
analysis by including only treatment-naïve women to demonstrate the robustness of the results.  278 





Characteristics of included studies 284 
The final updated search yielded 709 non-duplicated studies (Figure 1). After screening the 285 
titles and abstracts, 636 irrelevant studies were excluded. Finally, a total of 62 studies (61 286 
publications, 9356 women) fulfilled the inclusion criteria and were included. These studies 287 
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were published in English (n=58), French (n=1) (Boudhraa, et al., 2010), Italian (n=1) 288 
(Santonocito, et al., 2009), Turkish (n=1) (Aygen, et al., 2007) and Persian (n=1) (Lorzadeh, 289 
et al., 2011). 290 
IPD was not sought from eight studies (575 women), due to insufficient contact information 291 
(n=6; 359 women) (Beigi, 2006, Boudhraa, et al., 2010, Cudmore and Tupper, 1966, El-Biely 292 
and Habba, 2001, Garcia, et al., 1985, Johnson, et al., 1966) or because the studies were 293 
identified after our data requesting timeline (n=2; 216 women) (Fatima, et al., 2018, Topçu, et 294 
al., 2017). For the remaining 54 studies (8781 women), the primary investigators were 295 
contacted to share IPD of the primary studies. IPD from 34 studies (4819 women) were not 296 
available, due to no response (n=23; 3258 women) (Abuelghar, et al., 2013, Atay, et al., 2006, 297 
Ayaz, et al., 2013, Banerjee Ray, et al., 2012, Basirat, et al., 2012, Boostanfar, et al., 2001, 298 
Chen, et al., 2016, Dasari and Pranahita, 2009, Dehbashi, et al., 2009, Hossein-Rashidi, et al., 299 
2016, Jahan, 2015, Karimzadeh, et al., 2007, Karimzadeh and Javedani, 2010, Lopez, et al., 300 
2004, Lorzadeh, et al., 2011, Maged, et al., 2015, Robinson, et al., 2003, Roy, et al., 2012, 301 
Selim and Borg, 2012, Seyedoshohadaei, et al., 2012, Sharief and Nafee, 2015, Sheikh-El-Arab 302 
Elsedeek and Elmaghraby, 2011, Zeinalzadeh, et al., 2010), data loss (n=10; 1411 women) 303 
(Aygen, et al., 2007, Badawy, et al., 2009, Badawy and Gibreal, 2011, Fleming, et al., 2002, 304 
Keikha and Shahraki Mojahed, 2011, Khorram, et al., 2006, Mobusher, 2014, Santonocito, et 305 
al., 2009, Tang, et al., 2006, Zain, et al., 2009) or legal reasons (n=1; 150 women) (Moussa, et 306 
al., 2016). The details of these studies are listed in Supplementary Table 1. 307 
IPD were available for at least one outcome from 20 studies (3962 women), including three 308 
from the US (Legro, et al., 2007, Legro, et al., 2014, Williams, et al., 2009), three from Italy 309 
(Leanza, et al., 2014, Palomba, et al., 2005, Vegetti, et al., 1999), three from Turkey (Bayar, et 310 
al., 2006, Nazik and Kumtepe, 2012, Sahin, et al., 2004), two from the UK (Amer, et al., 2017, 311 
Lord, et al., 2006), two from China (Liu, et al., 2017, Wu, et al., 2017), two from India (Kar, 312 
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2012, Kar and Sanchita, 2015), two studies (in one publication) from New Zealand (Johnson, 313 
et al., 2010), one from The Netherlands (Moll, et al., 2006), one from Finland (Morin-Papunen, 314 
et al., 2012) and one from multiple countries (The Netherlands, UK, Malta, Belgium, Argentina 315 
and Colombia) (Homburg, et al., 2012). These RCTs were published in English between 1999 316 
and 2017, with 11 (55%) published after 2010.  317 
Participants in all 20 RCTs were women with PCOS. In one RCT, participants were diagnosed 318 
with PCOS by fulfilling at least three of the following: PCO morphology, oligo/amenorrhoea, 319 
hirsutism, hyperandrogenaemia and elevated serum LH/FSH ratio (Sahin, et al., 2004); while 320 
in the remaining 19 RCTs, the participants were women with PCOS based on the Rotterdam 321 
criteria (Bayar, et al., 2006, Kar, 2012, Leanza, et al., 2014, Liu, et al., 2017, Nazik and 322 
Kumtepe, 2012) or different phenotypes, including Phenotype B (ovulatory dysfunction + 323 
androgen excess) (Amer, et al., 2017, Homburg, et al., 2012, Johnson, et al., 2010, Kar and 324 
Sanchita, 2015, Legro, et al., 2007, Legro, et al., 2014, Lord, et al., 2006, Morin-Papunen, et 325 
al., 2012, Palomba, et al., 2005, Williams, et al., 2009, Wu, et al., 2017) or Phenotype D 326 
(ovulatory dysfunction + PCO) (Moll, et al., 2006, Vegetti, et al., 1999). 327 
For RCTs involving two stages of different interventions, including cross-over studies, we only 328 
included the data in the first stage. We included the IPD comparing letrozole versus CC before 329 
crossing over (Amer, et al., 2017) and included the IPD comparing metformin versus placebo 330 
within the first three months before starting other ovulation induction agents (Morin-Papunen, 331 
et al., 2012). In one RCT (Nazik and Kumtepe, 2012), switching between intervention and the 332 
control after the first cycle was allowed during the trial and the analysis in the primary 333 
publication was on a per-cycle basis; and therefore we only included the IPD of the first cycle. 334 
In summary, four RCTs compared three interventions (CC plus metformin or CC alone versus 335 
metformin (Johnson, et al., 2010, Kar and Sanchita, 2015, Legro, et al., 2007) or CC with 336 
metformin or letrozole versus CC (Liu, et al., 2017)) and the remaining 16 compared two 337 
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interventions. The most common comparisons were CC with metformin versus CC alone (8 338 
RCTs) (Johnson, et al., 2010, Kar and Sanchita, 2015, Leanza, et al., 2014, Legro, et al., 2007, 339 
Liu, et al., 2017, Moll, et al., 2006, Sahin, et al., 2004, Williams, et al., 2009) and letrozole 340 
versus CC alone (6 RCTs) (Amer, et al., 2017, Bayar, et al., 2006, Kar, 2012, Legro, et al., 341 
2014, Liu, et al., 2017, Nazik and Kumtepe, 2012). 342 
 343 
Quality of evidence of individual studies 344 
The details of risks of bias assessments within individual studies are presented in Figure 2. All 345 
RCTs (n=20) reported adequate methods of random sequence generation. Sixteen RCTs (80%) 346 
reported adequate methods of allocation concealment while the other four used an open 347 
allocation schedule without concealment (Kar, 2012, Kar and Sanchita, 2015, Liu, et al., 2017, 348 
Nazik and Kumtepe, 2012). Fourteen RCTs (70%) blinded the participants and personnel 349 
during the trial while six RCTs applied an open label design (Homburg, et al., 2012, Kar, 2012, 350 
Kar and Sanchita, 2015, Liu, et al., 2017, Nazik and Kumtepe, 2012, Vegetti, et al., 1999). 351 
Given that all outcomes of interest were objective outcomes, it is unlikely that the non-blinded 352 
design will affect the outcome measurement and therefore detection bias was rated at low risk 353 
for all the included studies. One RCT (5%) had high risk of attrition bias, with 22% overall 354 
missing outcome data and 31% missing outcome data in the metformin group (Kar and 355 
Sanchita, 2015). One RCT (5%) was at another risk of bias due to allowing imbalanced co-356 
intervention (CC) in both groups. 357 
 358 
Meta-analyses of letrozole versus CC 359 
Live birth 360 
IPD were available in six RCTs comparing letrozole and CC, including 1284 women with 361 
PCOS. The forest plot of IPD Meta-analysis on live birth is presented in Figure 3a. Compared 362 
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with CC, letrozole increased live birth rates (3 RCTs, 1043 women, RR 1.43, 95% CI 1.17-363 
1.75, I2=0, moderate certainty of evidence). Sensitivity analysis on studies with low risk of bias 364 
at allocation concealment and on treatment-naïve women were consistent with the main 365 
findings (2 RCTs, 909 women, RR 1.42, 95% CI 1.14-1.76, I2=0; 3  RCTs, 627 women, RR 366 
1.41, 95%CI 1.11-1.79, I2=0) (Supplementary Table 2). 367 
Secondary outcomes 368 
Compared with CC alone, letrozole improved clinical pregnancy (6 RCTs, 1284 women, RR 369 
1.45, 95%CI 1.23-1.70, I2=0, moderate certainty of evidence, Figure 3b) and ovulation rates (5 370 
RCTs, 1210 women, RR 1.13, 95%CI 1.07-1.20, I2=0, moderate certainty of evidence, Table 371 
2). There was insufficient evidence of a difference between letrozole and CC alone in terms of 372 
multiple pregnancy or miscarriage (Table 2). 373 
The summary Kaplan-Meier curve for time to pregnancy is presented in Figure 4a. Subsequent 374 
pooled analysis of HRs showed that compared to CC, letrozole improved time-to-pregnancy (6 375 
RCTs, 1235 women, HR 1.72, 95%CI 1.38-2.15, I2=0, moderate certainty of evidence). 376 
Treatment-covariate interactions 377 
A meta-analyses of effect modifications showed a positive interaction between baseline serum 378 
total testosterone levels and treatment effects on live birth in the comparison between letrozole 379 
and CC (interaction RR 1.29, 95%CI 1.01-1.65, 3 RCTs, 1039 women, Figure 5a). This 380 
suggests that women with a higher baseline serum total testosterone level have a larger 381 
treatment effect of letrozole versus CC on live birth, compared to women with a lower baseline 382 
serum total testosterone level. Such an interaction was consistent across studies (I2=0). To 383 
directly illustrate the association between baseline serum total testosterone level and relative 384 
treatment effects, this interaction is also presented in a weighted mean curve with 95% CI 385 




Meta-analyses of CC plus metformin versus CC 388 
Live birth 389 
IPD were available in eight RCTs comparing CC with metformin and CC alone, including 1039 390 
women with PCOS. The forest plot of IPD Meta-analysis on live birth is presented in Figure 391 
3c. Compared with CC alone, there was insufficient evidence of a difference between CC with 392 
metformin and CC alone on live birth (5 RCTs, 907 women, RR 1.08, 95%CI 0.87-1.35, 393 
I2=5.6%, low certainty of evidence). Sensitivity analyses on studies with low risk of bias at 394 
allocation concealment and on treatment-naïve women showed very small treatment effects 395 
with wide CIs (3 RCTs, 714 women, RR 1.02, 95%CI 0.76-1.37, I2=33.2%; 5 RCTs, 662 396 
women, RR 1.06, 95%CI 0.83-1.34, I2=3.9%) (Supplementary Table 2). 397 
Secondary outcomes 398 
Compared with CC alone, CC with metformin might improve clinical pregnancy (8 RCTs, 399 
1039 women, RR 1.18, 95% CI 1.00-1.39, I2=6.9%, low certainty of evidence, Figure 3b). 400 
There was insufficient evidence of a difference between CC with metformin and CC alone on 401 
ovulation, multiple pregnancy or miscarriage (Table 2). 402 
The summary Kaplan-Meier curve is presented in Figure 4b. Pooled analysis of HRs showed 403 
that compared to CC alone, CC with metformin might improve time-to-pregnancy (7 RCTs, 404 
898 women, HR 1.25, 95%CI 1.00-1.57, I2=0, low certainty of evidence). 405 
Treatment-covariate interactions 406 
Meta-analyses of effect modifications showed a positive interaction between baseline insulin 407 
levels and treatment effects on live birth in the comparison between CC with metformin and 408 
CC alone (interaction RR 1.03, 95%CI 1.01-1.06, 4 RCTs, 741 women, Figure 5c). Such an 409 
interaction was consistent across studies (I2=0). This suggests that women with a higher 410 
baseline serum insulin level have larger treatment effects of CC with metformin versus CC 411 
alone on live birth, compared to women with a lower baseline serum insulin level. Such an 412 
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interaction was also presented in a weighted mean curve with 95%CI (Figure 5d). Additional 413 
meta-analysis of interactions for HOMA-IR was performed as requested during the peer review 414 
process and it also showed a positive interaction between baseline HOMA-IR and treatment 415 
effects on live birth in the comparison between CC with metformin and CC alone (interaction 416 
RR 1.14, 95%CI 1.03-1.25, 4 RCTs, 736 women, I2=0, Table 3). Meta-analyses did not find 417 
any other treatment-covariate interactions (Table 3). 418 
 419 
IPD availability bias 420 
With regards to IPD availability bias, network meta-analyses of 20 RCTs with IPD showed 421 
similar results to network meta-analyses of all eligible RCTs on both live birth and clinical 422 
pregnancy (Supplementary Table 3). Therefore, the participants in RCTs with IPD were 423 
representative of all the eligible participants with PCOS. The transitivity assumption of 424 
network meta-analyses was considered valid as the interventions of interest and placebo/no 425 




Summary of evidence 430 
This IPD meta-analysis showed that in women with PCOS, letrozole increased live birth rates 431 
compared to CC alone and the overall certainty of evidence was moderate. Such treatment 432 
benefits of letrozole compared to CC alone were more predominant in women with higher 433 
baseline serum levels of total testosterone. There was insufficient evidence of a difference 434 
between CC plus metformin and CC alone in live birth rates and the overall certainty of 435 
evidence was low, mainly due to risk of bias and imprecision. The potential benefit of CC in 436 
combination with metformin compared to CC alone were more pronounced in women with 437 
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higher baseline serum insulin or HOMA-IR levels. We did not find other treatment-covariate 438 
interactions on live birth for other prespecified covariates including age, BMI, ethnicity, 439 
primary/secondary infertility, treatment history, Ferriman–Gallwey score for hirsutism, SHBG, 440 
free androgen index, fasting glucose levels or ovarian volume. 441 
 442 
Strengths and limitations 443 
Establishing the International Ovulation Induction IPDMA Collaboration facilitated a platform 444 
for key trialists in PCOS to collaborate and share the IPD of the primary trials. It provided us 445 
the opportunity to collect unpublished information of the primary trials including the details of 446 
randomisation and allocation concealment, treatment history, subgroup data and time-to-447 
pregnancy. Such information allowed us to assess the quality of included trials precisely, to 448 
investigate treatment-covariate interactions and to take account of the time in the analyses. The 449 
findings of this IPD meta-analysis provide the best available up-to-date evidence. 450 
Moreover, we applied a comprehensive search strategy without language restrictions and 451 
updated the search after completing data requesting in case we missed the most recent RCTs. 452 
Of the newly identified RCTs, one compared CC plus metformin vs CC in 128 women but did 453 
not report live birth (Fatima, et al., 2018), while the other one compared tamoxifen vs CC in 454 
88 women (Topçu, et al., 2017). Although we did not seek IPD from two RCTs identified after 455 
the data requesting deadline, adding IPD of these two studies is unlikely to change the main 456 
findings.  457 
In addition, the investigation of subgroup effects includes within-study interaction only 458 
according to current statistical practice for IPD meta-analyses (Fisher, et al., 2017) and 459 
therefore are free from ecological bias. For continuous covariates, without categorisation of the 460 
data, the statistical power was not compromised. Further illustration of interactions in weighted 461 
mean curve makes the interactions easier to interpret. 462 
20 
 
Nevertheless, this IPD meta-analysis has a few limitations. First, we were not able to access 463 
the IPD of all eligible studies. IPD were available for 32% (20/62) of the included trials, 464 
comprising 42% (3962/9356) of the eligible women with PCOS and the proportions of IPD 465 
availability was higher for studies reporting live birth (44% trials including 65% eligible 466 
women, Supplementary Table 3). This seems to be partly due to the long history of research 467 
on ovulation induction, with the first trial published in 1966. We were however able to access 468 
IPD of the highest-quality trials published within the last 15 years and we did not detect 469 
evidence of availability bias. Second, most of the planned subgroup analyses were based on 470 
two to three of the included studies and therefore may still be underpowered due to the 471 
unavailability of data on relevant covariates and/or live birth. Some primary trials only included 472 
a relatively homogeneous ethnicity group and therefore IPD in such trials could not contribute 473 
to the analysis of treatment-ethnicity interaction as no within-trial interaction was available. 474 
Third, as treatment-resistant women were excluded from this IPD meta-analysis, the findings 475 
can be applied in clinical practice on the choice of first-line treatment only. Last, we planned a 476 
one-stage IPD meta-analysis in the protocol but decided to use a two-stage approach before the 477 
final analysis. A two-stage approach allows graphical presentations for both overall treatment 478 
effects and treatment-covariate interactions, which is important for clinical interpretation, 479 
while it is not obvious how best to present graphically the results of a one-stage model (Fisher, 480 
et al., 2017). In addition, the two-stage approach automatically avoids ecological bias by 481 
accounting for within-trial interactions only (Fisher, et al., 2017). Given the relatively large 482 
number of participants, low heterogeneity and overall good to moderate quality of included 483 
studies, we would expect both approaches to give very similar results. 484 
 485 
Interpretations and clinical implications 486 
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The overall effects of letrozole and CC plus metformin vs CC on live birth and clinical 487 
pregnancy in this IPD meta-analysis were in agreement with existing systematic reviews 488 
(Franik, et al., 2018, Morley, et al., 2017, Wang, et al., 2017) as well as the most recent the 489 
international evidence-based guideline recommendations (Teede, et al., 2018). Based on the 490 
findings of this IPD meta-analysis, letrozole can be recommended as the first-line ovulation 491 
induction medication in women with PCOS and infertility, provided off-label use is allowed 492 
and women are fully informed. Compared to CC alone, CC plus metformin may increase 493 
clinical pregnancy rates but the evidence on live birth was insufficient. Sensitivity analysis 494 
showed that the treatment effects on live birth seemed very small. The discrepancies between 495 
clinical pregnancy and live birth were likely due to the bias arising from low quality of studies 496 
which did not report live birth. Further evidence is needed to address this question. 497 
Subgroup analyses showed that women with higher baseline serum levels of total testosterone 498 
may benefit more from letrozole compared to CC and women with higher baseline serum levels 499 
of insulin may benefit more from CC plus metformin compared to CC alone. Such positive 500 
interactions were consistent across trials and supported from a biological perspective. Letrozole 501 
has been introduced as an ovulation induction agent since 2001 and it inhibits aromatase, 502 
therefore increasing gonadotropin secretion by release of the hypothalamic/pituitary axis from 503 
estrogenic negative feedback and resulting in stimulation of ovarian follicle development 504 
(Mitwally and Casper, 2001). According to the recent “two triangles hypothesis” for 505 
folliculogenesis in PCOS, pre-antral follicle growth is excessive due to intrinsic androgen 506 
excess that renders granulosa cells hypersensitive to FSH, with consequently excessive AMH 507 
expression (Dewailly, et al., 2016) Therefore, hyperandrogenaemia may improve the response 508 
to letrozole by enhancing the sensitivity of FSH receptors. However, such an interaction was 509 
not observed in other biomarkers of hyperandrogenaemia or hirsutism. This is likely due to the 510 
fact that the severity of hirsutism does not correlate well with the magnitude of androgen 511 
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excess, as hirsutism is an expression of hyperandrogenism on hair follicles mediated through 512 
different pathways from those affecting the ovaries and follicles (Escobar-Morreale, et al., 513 
2012). Metformin is an insulin sensitising agent that decreases gluconeogenesis and lipogenesis 514 
and enhances peripheral glucose uptake and therefore increases insulin sensitivity (Naderpoor, 515 
et al., 2015). The addition of metformin may further improve insulin resistance in women with 516 
higher fasting insulin or HOMA-IR levels and therefore improve pregnancy outcomes. We 517 
acknowledge that insulin levels are affected by many factors, ranging from physical activity 518 
and pre-test duration of fasting to sample handling and assay variability (Cassar, et al., 2016). 519 
Therefore the international evidence-based guideline does not recommend clinical 520 
measurement of insulin resistance at present due to the lack of accuracy (Teede, et al., 2018). 521 
In addition, SHBG has been proposed as a measure of insulin resistance (Cassar, et al., 2016), 522 
but the findings in our IPD meta-analysis did not support treatment-by-SHBG interactions. Our 523 
work provides preliminary evidence that there may be a role for assessing insulin resistance in 524 
PCOS and infertility and supports the need to assess insulin resistance in infertility studies. 525 
We did not find ethnicity differences on treatment effects. This could be partly due to self-526 
reported ethnicity without objective or DNA validation in all trials. We also did not find other 527 
treatment-covariate interactions on live birth for other prespecified covariates including age, 528 
BMI, primary/secondary infertility, treatment history, Ferriman–Gallwey score for hirsutism, 529 
SHBG, free androgen index, fasting glucose levels or ovarian volume. Although analyses of 530 
subgroup effects were prespecified in the protocol, these results should still be considered 531 
exploratory due to multiplicity.  532 
Time is an important measurement for infertility outcomes, especially in the assessment of the 533 
effectiveness of multi-cycle treatments. However, time-to-event outcomes have seldomly been 534 
reported in meta-analyses of infertility trials as fertility outcomes are usually considered as 535 
dichotomous outcomes and Kaplan-Meier curves are rarely presented. Our IPD meta-analysis 536 
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used number of cycles as a measure of time and evaluated time-to-pregnancy by estimating 537 
HRs and presenting summary Kaplan-Meier curves. Time-to-event analysis takes time and 538 
censored participants into account and provides more accurate estimates of treatment effect. 539 
Our analyses on time-to-pregnancy were inconsistent with those of clinical pregnancy. 540 
 541 
Research implications 542 
IPD meta-analyses are useful to inform the design, conduct, analysis, and interpretation of trials 543 
(Tierney, et al., 2015). Given the consistent treatment benefits of letrozole across different 544 
fertility outcomes, future trials investigating new interventions for PCOS should choose 545 
letrozole as the reference arm. New trials are encouraged to incorporate treatment selection 546 
markers in their design to guide treatment decision (Janes, et al., 2011), and the impact of these, 547 
including age, BMI and other biomarkers, need to be confirmed in future trials. More 548 
specifically, biomarkers for hyperandrogenaemia and insulin resistance could be applied in 549 
trials that evaluate metformin. Due to the limited accuracy for measuring existing insulin 550 
resistance biomarkers, optimal methods to assess insulin resistance in future trials should also 551 
be considered. 552 
Developing and implementing a core outcome set for infertility (Duffy, et al., 2018) and PCOS 553 
should be recommended to ensure outcomes are reported and collected consistently across 554 
future trials on infertility and PCOS to reduce research waste .  555 
 556 
Conclusions 557 
Our IPD meta-analysis shows that in women with PCOS, letrozole improves live birth and 558 
clinical pregnancy rates and reduces time-to-pregnancy compared to CC alone. CC plus 559 
metformin may improve clinical pregnancy rates and may reduce time-to-pregnancy compared 560 
to CC alone, but there is insufficient evidence of a difference on live birth.  561 
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Treatments effects of letrozole are influenced by baseline serum levels of total testosterone 562 
while those of CC plus metformin are affected by baseline serum levels of insulin. These 563 
interactions between treatments and biomarkers on hyperandrogenaemia and insulin resistance 564 
provide further insights into a personalised approach towards the clinical management of 565 
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Figure legends 874 
Figure 1. PRISMA-IPD flow diagram 875 
Figure 2. Risk of bias assessments of individual RCTs 876 
Figure 3. Meta-analyses of letrozole versus CC and CC plus metformin versus CC on live 877 
birth and clinical pregnancy 878 
Figure 4. Summary Kaplan-Meier curves for time-to-event outcomes 879 
Figure 4a-4b illustrate the non-stratified summary Kaplan-Meier curves for time-to-880 
pregnancy in the comparisons of letrozole versus CC and CC plus metformin versus CC, 881 
respectively.  882 
Participants with pregnancy before the first treatment cycles were not included in the 883 
'Numbers at risk' table below and data were not stratified by trial in this Kaplan-Meier curve. 884 
The figures were intended to visualise time-to-event outcomes, but not to show statistical 885 
significance. 886 
Figure 5. Forest plots and weighted mean curves for treatment-covariate interactions 887 
5a. Forest plot of interactions between baseline serum total testosterone (TT) level and effect 888 
of letrozole versus CC on live birth.  889 
5b. Weighted mean curve with pointwise 95% CI of interactions between baseline serum total 890 
testosterone level and relative effect of letrozole versus CC on live birth. 5c. Forest plot of 891 
interactions between baseline serum insulin level and effect of CC plus metformin versus CC 892 
on live birth.  893 
5d. Weighted mean curve with pointwise 95% CIs of interactions between baseline serum 894 
insulin level and effect of CC plus metformin versus CC on live birth. 895 
5a,c. Circles are used to depict the interaction effects within individual trials as well as the 896 
overall interaction effect. The sizes of the circles are in proportion to the inverse of the 897 
variance of the estimates. 898 
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5b,d. Blue line represents for the weighted mean effect of covariate on log risk ratios in the 899 
comparison between letrozole and CC. Red lines represent for pointwise 95% CI of 900 
interactions. 901 
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